UK-based biotech firm raises $45 M

BioSpectrum (Asia) - - World News -

Lon­don-based Night­star, a com­pany that de­vel­ops treat­ments for reti­nal dis­eases, raised $45 mil­lion in fund­ing from sev­eral in­vestors in­clud­ing Welling­ton Man­age­ment Com­pany, Red­mile Group, Syn­cona, and New En­ter­prise As­so­ci­ates in a Series C fi­nanc­ing round.

Night­star is a biotech­nol­ogy com­pany that cur­rently de­vel­ops reti­nal gene ther­apy so­lu­tions for those with reti­nal dys­tro­phies. These are in­tended to be one-time treat­ments to pre­vent even­tual blind­ness. Night­star is cur­rently re­search­ing and eval­u­at­ing sev­eral gene ther­apy prod­ucts.

The com­pany plans to use the in­vest­ment to com­plete clin­i­cal tri­als for their gene ther­apy prod­ucts aimed at choroi­deremia, re­tini­tis pig­men­tosa, and mac­u­lar dys­tro­phy. Night­star is build­ing a pipe­line of prod­uct can­di­dates based on in­dus­try-lead­ing gene ther­apy tech­nol­ogy and oph­thal­mol­ogy ex­per­tise.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.